XASE · APUS
-5.49% · -$0.2700 · Vol 16.9K
After hours · updated 16:10:00 ET
Apimeds Pharmaceuticals US, Inc.

Apimeds Pharmaceuticals US, Inc.

PHARMACEUTICAL PREPARATIONS
$4.65
Card
Relationship Map

Veridion Score

BETALOW CONF · 4/6 factorsMethodology
APUS
Apimeds Pharmaceuticals US, Inc.
Stale score · Tue Aug 4 · completed session · 23h old · Scheduled each trading day · Markets closed · resumes Thu 9:30 ET
SELL BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

43/ 100
Veridion Score
SELL BIAS · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 4/6 factors with data · Stale score · Tue Aug 4 · completed session · 23h old · Scheduled each trading day · Markets closed · resumes Thu 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is APUS moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading APUS catalysts
About Apimeds Pharmaceuticals US, Inc.
PHARMACEUTICAL PREPARATIONS
Listed since
2025
Employees
7
Country
US

Apimeds Pharmaceuticals Us Inc is a development-stage biopharmaceutical company. The Company operates its biopharmaceutical business. Its primary focus is the clinical development of Apitox, a purified honeybee venom-based drug candidate being evaluated for the treatment of pain and inflammation associated with knee osteoarthritis. The Company operates in two segments: the biopharmaceutical segment, which is focused on the clinical development of Apitox through Lokahi, and the digital asset operations segment, which encompasses the holding, sale, and advancement of the MindWaveDAO blockchain and related digital assets through MindWave.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$4.77
Day high
$5.16
Day low
$4.65
Previous close
$4.92
52W high
$38.95
-88.06% from high
52W low
$4.65
0% of range
Market cap
$7.4M
EPS
$-3.5467
Beta
0.88
Shares out
1.5M
Volume
16.9K
0.46× rel vol
Avg volume
36.7K
VWAP
$4.68
Price history computed in-house
1W
-19.13%
1M
-45.93%
3M
-67.93%
1Y
-72.16%
YTD
-71.65%
SMA 50 $9.36 · below
SMA 200 $16.21 · below
52W position 0%

APUS overview

Veridion Score
43
4 of 6 factors measured
Congress receipts
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around APUS.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading APUS Form 4 filings
Public disclosures

Congress activity in APUS

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for APUS in the cached public ledger.

Federal contracts

APUS contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for APUS in this window.
Lobbying spend

APUS lobbying filings, year to date.

Registered lobbying filings matched to Apimeds Pharmaceuticals US, Inc..

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for APUS in this window.
Loading news for APUS
Analyst ratings
Sovereign unlock shows live analyst consensus for APUS.
Options
Sovereign unlock shows live options positioning for APUS.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.